HER-2 overexpression has previously been reported to be associated with claudin 420 and paxillin expression21 in breast carcinomas, which led us to further investigate whether, in our set of non-nodular breast lesions, this association would be confirmed. Here, ERBB2 is linked to breast carcinoma.